Market Cap 2.28B
Revenue (ttm) 108.30M
Net Income (ttm) -97.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.58%
Debt to Equity Ratio 0.00
Volume 3,701,900
Avg Vol 7,573,374
Day's Range N/A - N/A
Shares Out 167.18M
Stochastic %K 3%
Beta -1.82
Analysts Strong Sell
Price Target $32.88

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 ant...

Industry: Biotechnology
Sector: Healthcare
Phone: 65 6236 3388
Address:
Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore
B_B_
B_B_ Jan. 20 at 1:17 PM
$WVE Maybe the ex-partner (Pfizer) will return now that they share the same interests (obesity). May 5, 2016 Pfizer, WAVE Life Sciences Launch Up-to-$911M+ Metabolic Disease Collaboration https://www.genengnews.com/news/pfizer-wave-life-sciences-launch-up-to-911m-metabolic-disease-collaboration/
0 · Reply
B_B_
B_B_ Jan. 20 at 1:02 PM
$WVE unfortunately not WVE GSK scoops up RAPT Therapeutics for $2.2BN The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company. Annabel Kartal Allen January 20, 2026 https://www.pharmaceutical-technology.com/news/gsk-rapt-therapeutics-acquisition-2-2bn-immunology-food-allergy/
0 · Reply
B_B_
B_B_ Jan. 20 at 9:37 AM
$WVE (2/2) "Now we see that this operates almost like Viagra, where people were willing to pay and buy it, although it was not reimbursed at all." … "We are all in on obesity," Bourla said. … Pfizer has said it expects the next few years to be bumpy, due to the expiration of patents on key drugs, … https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-plans-soaring-consumer-market-obesity-drugs-akin-viagra-2026-01-12/
0 · Reply
B_B_
B_B_ Jan. 20 at 9:37 AM
$WVE (1/2) Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra By Michael Erman January 13, 2026 Summary - Pfizer CEO Bourla says cash-pay market larger than anticipated … "Both Lilly and Novo presented their sales and had significant sales outside the reimbursement system. …
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 17 at 1:26 AM
$WVE Share Price: $13.65 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $3.48 – $4.30 Target Zone: $5.94 – $7.26 Potential Upside: 61% ROI Time to Expiration: 335 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
nycpupster
nycpupster Jan. 16 at 7:38 PM
$WVE another speculative biotech with novel RNA based pipeline. This one is either a 50% down or 300% up stock, so size appropriately
0 · Reply
B_B_
B_B_ Jan. 16 at 6:06 PM
$WVE I think Monday will be a positive day, even without any M&A activity. After a 33% drop, the share price should recover, free from the pressure of options traders. WVE does not have weekly options, and the next options expiration is five weeks away.
0 · Reply
B_B_
B_B_ Jan. 16 at 5:33 PM
$WVE After a large purchase of 500,000+ shares at 11:33, will there be another significant buyer stepping in later today?
0 · Reply
B_B_
B_B_ Jan. 16 at 3:09 PM
0 · Reply
B_B_
B_B_ Jan. 16 at 2:57 PM
0 · Reply
Latest News on WVE
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.

Jan 13, 2026, 8:26 PM EST - 6 days ago

Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.


Why Did Wave Life Sciences Surge 147%?

Dec 15, 2025, 6:30 AM EST - 5 weeks ago

Why Did Wave Life Sciences Surge 147%?


What's Going On With Wave Life Sciences Stock Tuesday?

Dec 9, 2025, 2:11 PM EST - 5 weeks ago

What's Going On With Wave Life Sciences Stock Tuesday?


Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 8:01 PM EST - 2 months ago

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript


Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 7, 2025, 8:30 AM EST - 2 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences


Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 9:38 PM EDT - 6 months ago

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript


Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 9, 2025, 4:57 PM EDT - 9 months ago

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript


Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 3:16 PM EST - 11 months ago

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript


Wave Life Sciences Is A Buy On Pipeline Prospects

Jan 8, 2025, 1:35 AM EST - 1 year ago

Wave Life Sciences Is A Buy On Pipeline Prospects


Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 12:20 PM EST - 1 year ago

Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript


B_B_
B_B_ Jan. 20 at 1:17 PM
$WVE Maybe the ex-partner (Pfizer) will return now that they share the same interests (obesity). May 5, 2016 Pfizer, WAVE Life Sciences Launch Up-to-$911M+ Metabolic Disease Collaboration https://www.genengnews.com/news/pfizer-wave-life-sciences-launch-up-to-911m-metabolic-disease-collaboration/
0 · Reply
B_B_
B_B_ Jan. 20 at 1:02 PM
$WVE unfortunately not WVE GSK scoops up RAPT Therapeutics for $2.2BN The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company. Annabel Kartal Allen January 20, 2026 https://www.pharmaceutical-technology.com/news/gsk-rapt-therapeutics-acquisition-2-2bn-immunology-food-allergy/
0 · Reply
B_B_
B_B_ Jan. 20 at 9:37 AM
$WVE (2/2) "Now we see that this operates almost like Viagra, where people were willing to pay and buy it, although it was not reimbursed at all." … "We are all in on obesity," Bourla said. … Pfizer has said it expects the next few years to be bumpy, due to the expiration of patents on key drugs, … https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-plans-soaring-consumer-market-obesity-drugs-akin-viagra-2026-01-12/
0 · Reply
B_B_
B_B_ Jan. 20 at 9:37 AM
$WVE (1/2) Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra By Michael Erman January 13, 2026 Summary - Pfizer CEO Bourla says cash-pay market larger than anticipated … "Both Lilly and Novo presented their sales and had significant sales outside the reimbursement system. …
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 17 at 1:26 AM
$WVE Share Price: $13.65 Contract Selected: Dec 18, 2026 $15 Calls Buy Zone: $3.48 – $4.30 Target Zone: $5.94 – $7.26 Potential Upside: 61% ROI Time to Expiration: 335 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
nycpupster
nycpupster Jan. 16 at 7:38 PM
$WVE another speculative biotech with novel RNA based pipeline. This one is either a 50% down or 300% up stock, so size appropriately
0 · Reply
B_B_
B_B_ Jan. 16 at 6:06 PM
$WVE I think Monday will be a positive day, even without any M&A activity. After a 33% drop, the share price should recover, free from the pressure of options traders. WVE does not have weekly options, and the next options expiration is five weeks away.
0 · Reply
B_B_
B_B_ Jan. 16 at 5:33 PM
$WVE After a large purchase of 500,000+ shares at 11:33, will there be another significant buyer stepping in later today?
0 · Reply
B_B_
B_B_ Jan. 16 at 3:09 PM
0 · Reply
B_B_
B_B_ Jan. 16 at 2:57 PM
0 · Reply
B_B_
B_B_ Jan. 16 at 2:09 PM
$WVE M&A Outlook 2026: Expectations Are High—Again By Jens Kengelbach, Daniel Friedman, and Dominik Degen January 15, 2026 ... Health Care. This sector—particularly pharmaceuticals—remains an “always-on” for M&A. Global incumbents consistently seek promising targets to refresh pipelines, expand portfolios, and reinforce long-term growth. A recent deal highlighting the competition for promising targets is Pfizer’s acquisition of obesity drug developer Metsera, for which Novo Nordisk also submitted an offer. This steady strategic demand is likely to sustain activity in 2026. ... https://www.bcg.com/publications/2026/m-and-a-outlook-expectations-are-high-again
0 · Reply
Quantumup
Quantumup Jan. 16 at 1:20 PM
Cantor reiterated $ARWR at an Overweight rating. $LLY $IONS $RHHBY REGN TEVA $WVE Here's what Cantor had to say: Early data for the INHBE and tirzepatide combination in obese and diabetic patients are very intriguing, but management also acknowledged the data are still very early. For the next update, ARWR aims to provide a more comprehensive readout across cohorts, which is why the company is not committing to specific timelines except to say "additional data in 2026." Due to the current regulatory environment for obesity drugs, the goal is to demonstrate incremental (higher quality) weight loss, which is one of the key reasons to prioritize the obese and diabetic cohort.
0 · Reply
B_B_
B_B_ Jan. 16 at 12:30 PM
$WVE On April 18, 2023, GSK reached an agreement to acquire the late-stage biopharmaceutical company BELLUS Health. Prior to the offer, BELLUS's stock price had dropped by 33% over a period of five months. Luke Miels, who was GSK’s Chief Commercial Officer at the time, championed the BELLUS acquisition. Now, as CEO of GSK, could Luke Miels once again be responsible for the acquisition of WVE, following the recent 33% drop in WVE's stock price?
0 · Reply
B_B_
B_B_ Jan. 16 at 9:39 AM
$WVE GSK was a pioneer in over-the-counter (OTC) obesity treatment with Alli (orlistat 60 mg). Could it be the first again to introduce an RNA-based obesity treatment with WVE-007? GSK should act quickly and make a deal with Wave Life Sciences before others zero in.
0 · Reply
B_B_
B_B_ Jan. 15 at 7:44 PM
$WVE "JP Morgan 2026: Obesity & GLP-1 Therapies Take Center Stage What the Latest Deals and Data Mean for the Future of Metabolic Medicine The J.P. Morgan Healthcare Conference once again served as the bellwether for where biotech and pharma are headed—and in 2026, GLP-1 and obesity therapeutics dominated the conversation. From next-generation incretin drugs to RNA-based obesity targets and ultra-long-acting formulations, this year’s announcements made one thing clear: we are entering a second (and more sophisticated) wave of obesity medicine."
0 · Reply
B_B_
B_B_ Jan. 15 at 7:41 PM
$WVE Day 1 @ JP Morgan in Obesity Drugs and Therapies ... Wave Life Sciences — WVE-007 Wave introduced one of the most unconventional obesity approaches at JPM: RNA interference targeting INHBE, a genetic regulator of fat mass. Single-dose data showed GLP-1–like fat loss Potential for once- or twice-yearly dosing Phase 2a multi-dose studies planned for 2026 Why it matters: This hints at a future where obesity may be treated like hyperlipidemia or osteoporosis—with infrequent dosing and long-acting control. ... https://cancerobesityconnection.org/day-1-jp-morgan/
0 · Reply
B_B_
B_B_ Jan. 15 at 5:04 PM
0 · Reply
B_B_
B_B_ Jan. 15 at 4:12 PM
0 · Reply
Stackdoe1
Stackdoe1 Jan. 15 at 3:42 PM
0 · Reply
B_B_
B_B_ Jan. 15 at 3:12 PM
$WVE This is the last day of the conference. A deal could happen by the end of the day, tomorrow, or on Monday, so I expect it to recover before the end of the day.
0 · Reply
B_B_
B_B_ Jan. 15 at 2:51 PM
$WVE (2/2) One not-so-secret agent, WVE-007, has the potential to serve as an effective treatment for obesity, which could reduce the need for medications and treatments for associated conditions and may ultimately lower healthcare costs under the Affordable Care Act. What a wonderful world that would be.
0 · Reply
B_B_
B_B_ Jan. 15 at 2:50 PM
$WVE (1/2) Obesity significantly harms health by increasing the risk of numerous serious conditions, including type 2 diabetes, heart disease, stroke, certain cancers (such as breast, colon, and endometrial cancer), sleep apnea, osteoarthritis, fatty liver disease, kidney disease, and mental health conditions like depression. These risks contribute to premature death, disability, and a reduced quality of life. Obesity affects the body by promoting chronic inflammation and placing excessive stress on joints, while also causing psychological distress, including low self-esteem and social stigma.
0 · Reply